Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 10209

Sort by

Sort Order Select

Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Blood (2021) 138 (11): 948–958.

https://doi.org/10.1182/blood.2020010144

Published: 2021

Includes: Supplemental data

Journal Articles

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

Danniel Zamora, Elizabeth R. Duke, Hu Xie, Bradley C. Edmison, Brenda Akoto, Richard Kiener, Terry Stevens-Ayers, Ralf Wagner, Marco Mielcarek, Wendy M. Leisenring, Keith R. Jerome, Joshua T. Schiffer, Greg Finak, Stephen C. De Rosa, Michael Boeckh

Blood (2021) 138 (1): 34–43.

https://doi.org/10.1182/blood.2020009396

Published: 2021

Includes: Supplemental data

Journal Articles

Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia

Paolo Simioni, Stefano Cagnin, Francesca Sartorello, Gabriele Sales, Luca Pagani, Cristiana Bulato, Sabrina Gavasso, Francesca Nuzzo, Francesco Chemello, Claudia M. Radu, Daniela Tormene, Luca Spiezia, Tilman M. Hackeng, Elena Campello, Elisabetta Castoldi

Blood (2021) 137 (17): 2383–2393.

https://doi.org/10.1182/blood.2020008168

Published: 2021

Includes: Supplemental data

Journal Articles

Cryptic insertion of KMT2A , a rare t(9;11) variant

Nada Assaf, Christine Terré

Blood (2021) 137 (13): 1843.

https://doi.org/10.1182/blood.2020010442

Published: 2021

Journal Articles

Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia

Malwine J. Barz, Jana Hof, Stefanie Groeneveld-Krentz, Jui Wan Loh, Annabell Szymansky, Kathy Astrahantseff, Arend von Stackelberg, Hossein Khiabanian, Adolfo A. Ferrando, Cornelia Eckert, Renate Kirschner-Schwabe

Blood (2020) 135 (12): 921–933.

https://doi.org/10.1182/blood.2019002499

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4403.

https://doi.org/10.1182/blood-2019-122952

Published: 2019

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

Journal Articles

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

Francesca Ferraro, MD PhD, Christopher A Miller, PhD, Amy Abdalla, Nichole Helton, Nathan Salomonis, PhD, Robert S Fulton, Catrina Fronick, BS, Sharon E Heath, Peter Westervelt, MD PhD, Timothy J Ley, MD

Blood (2019) 134 (Supplement_1): 3827.

https://doi.org/10.1182/blood-2019-122967

Published: 2019

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD, Dolores Schendel, Prof., Anna Tafuri, MD

Blood (2019) 134 (Supplement_1): 3923.

https://doi.org/10.1182/blood-2019-129749

Published: 2019

Journal Articles

Heme Oxygenase-1 in Leukemia Cells Promotes Cancer Associated Fibroblasts Mediating Progression of Acute Lymphoblastic Leukemia

Chengyun Pan, Dan Ma, MD, Qin Fang, Ping Liu, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 3958.

https://doi.org/10.1182/blood-2019-130440

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Xiaoqin Feng, Jian Li, MD, Chunfu Li, MD, Mincui Zheng, Honggui Xu, Yingyi He, MD& PhD, Changgang Li, MD, Hong Wen, Xiangling He, Lihua Yang, MD PhD

Blood (2019) 134 (Supplement_1): 3857.

https://doi.org/10.1182/blood-2019-126863

Published: 2019

Journal Articles

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 3750.

https://doi.org/10.1182/blood-2019-132220

Published: 2019

Journal Articles

Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML

Xin Long, PhD, Chris Man, PhD, Padmini Narayanan, PhD, Elizabeth Seashore, MD, Michele Redell, MD PhD

Blood (2019) 134 (Supplement_1): 3731.

https://doi.org/10.1182/blood-2019-129074

Published: 2019

Journal Articles

Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential

Jibran Durrani, Hassan Awada, Ashwin Kishtagari, MBBS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, Sanghee Hong, MD, Sunisa Kongkiatkamon, Alan Lichtin, MD, Aziz Nazha, MD, Bhumika J. Patel, MD, Yogenthiran Saunthararajah, MD, Hetty E. Carraway, MD MBA, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 3743.

https://doi.org/10.1182/blood-2019-129330

Published: 2019

Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 3938.

https://doi.org/10.1182/blood-2019-124072

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

NARROW

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia

Cryptic insertion of KMT2A , a rare t(9;11) variant

Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Heme Oxygenase-1 in Leukemia Cells Promotes Cancer Associated Fibroblasts Mediating Progression of Acute Lymphoblastic Leukemia

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML

Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only